Lornoxicam is a potent nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class, widely used in pharmaceutical field for analgesic, anti-inflammatory and antipyretic effects. It acts by balanced inhibition of cyclooxygenase-1 (COX-1) and COX-2, reducing prostaglandin synthesis without affecting lipoxygenase pathway. Clinically, it relieves moderate to severe pain including postoperative pain, rheumatoid arthritis, osteoarthritis, low back pain and cancer pain; also effective for fever reduction. Its advantages include rapid onset, long duration and high analgesic potency compared to other oxicams. In fine chemical industry, it serves as key intermediate for pharmaceutical synthesis. In research, it is used as tool compound to study COX enzymes and pain mechanisms.

GHS Classification: H315 (Causes skin irritation), H319 (Causes serious eye irritation), H335 (May cause respiratory irritation). Signal Word: Warning. Acute oral LD50 in rats >1000 mg/kg with low acute toxicity. Skin contact may cause redness, itching and dermatitis; rinse with water immediately if contaminated. Eye contact leads to severe irritation, tearing and conjunctivitis; flush with clean water for ≥15 minutes. Inhalation of dust irritates respiratory tract, causing cough and sore throat. Long-term use may cause gastrointestinal discomfort, headache and dizziness; contraindicated for peptic ulcer patients. It is toxic to aquatic organisms; avoid release to environment. Operate in well-ventilated area with nitrile gloves, goggles and dust mask. Store separately from food and oxidants; dispose waste per hazardous waste regulations.